Loading
A Japanese trial found vitamin D supplements did not help everyone after digestive cancer surgery, but appeared to help a subgroup identified by a tumour marker. That subgroup deserves its own trial.
The AMATERASU trial of vitamin D3 after surgery for digestive tract cancers was negative overall, but pre-specified and post-hoc analyses reported large relapse and death reductions in subgroups (p53-immunoreactive tumours, low-to-mid baseline vitamin D). Similar biomarker-restricted signals appeared in SUNSHINE (colorectal, high-dose vitamin D with chemotherapy). Vitamin D is nearly free. The proposal is a confirmatory randomised trial restricted to the biomarker-defined subgroup, with relapse-free survival as the primary endpoint, funded publicly.
Shares VITAL (VITamin D and OmegA-3 TriaL), Vitamin D and omega-3 supplementation.
Shares The Repurposing Drugs in Oncology (ReDO) Project, No incentive to repurpose cheap drugs, Colorectal cancer.
Shares The Repurposing Drugs in Oncology (ReDO) Project, No incentive to repurpose cheap drugs.
Shares The Repurposing Drugs in Oncology (ReDO) Project, No incentive to repurpose cheap drugs.
Shares The Repurposing Drugs in Oncology (ReDO) Project, No incentive to repurpose cheap drugs.
Shares The Repurposing Drugs in Oncology (ReDO) Project, No incentive to repurpose cheap drugs.
Shares The Repurposing Drugs in Oncology (ReDO) Project, No incentive to repurpose cheap drugs.
Shares The Repurposing Drugs in Oncology (ReDO) Project, No incentive to repurpose cheap drugs, Gastric & gastro-oesophageal junction cancer.